What is Apogee Therapeutics, Inc.'s stock issuance proceeds?

Apogee Therapeutics, Inc. (APGE) reported stock issuance proceeds of $378.17M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Apogee Therapeutics, Inc. APGE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

Summit TherapeuticsSMMT

$3.8M+88.1%

Arrowhead ResearchARWR

$46.83M—

Immunovant, Inc.IMVT

——

Protagonist TherapeuticsPTGX

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Operating income-$82.8M-31.2%

Net income-$74.1M-33.9%

EPS (diluted)-$1.06-11.6%

Balance sheet

See full

Cash & equivalents$451.8M+323%

Total debt$8.0M-31.9%

Total assets$1.3B+81.1%

Cash flow

See full

Operating cash flow-$55.6M-14.6%

CapEx$62.0K—

Free cash flow-$62.8M+7.3%

Valuation

See full

Market cap$6.81B+189%

Enterprise value$6.37B+181%

Returns & leverage

See full

Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s stock issuance proceeds?: Apogee Therapeutics, Inc. (APGE) reported stock issuance proceeds of $378.17M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.